Neurokinin-1 Receptor Antagonists

Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.

Also Known As:

Neurokinin-1 Receptor Blockers; Neuroleukin-1 Receptor Blockers; Substance P Receptor Antagonists; Substance P Receptor Blockers; Tachykinin Receptor 1 Antagonists; Tachykinin Receptor 1 Blockers; Antagonist, Neurokinin-1 Receptor; Antagonists, Neurokinin-1 Receptor; Blocker, Neurokinin-1 Receptor; Blocker, Neuroleukin-1 Receptor; Blockers, Neurokinin-1 Receptor; Blockers, Neuroleukin-1 Receptor; Neurokinin 1 Receptor Antagonists; Neurokinin 1 Receptor Blocker; Neurokinin 1 Receptor Blockers; Neuroleukin 1 Receptor Blocker; Neuroleukin 1 Receptor Blockers; Receptor Antagonist, Neurokinin-1; Receptor Antagonists, Neurokinin-1; Receptor Blocker, Neurokinin-1; Receptor Blocker, Neuroleukin-1; Receptor Blockers, Neurokinin-1; Receptor Blockers, Neuroleukin-1; Neurokinin 1 Receptor Antagonist; Neurokinin-1 Receptor Antagonist; Neurokinin-1 Receptor Blocker; Neuroleukin-1 Receptor Blocker; Substance P Receptor Antagonist; Substance P Receptor Blocker; Tachykinin Receptor 1 Antagonist; Tachykinin Receptor 1 Blocker

Networked: 306 relevant articles (46 outcomes, 51 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Neurotransmitter Agents: 13181
      - Neurokinin-1 Receptor Antagonists: 306
  - Physiological Effects of Drugs: 1
    - Neurotransmitter Agents: 13181
      - Neurokinin-1 Receptor Antagonists: 306

Experts

1.	Navari, Rudolph M: 15 articles (02/2020 - 06/2002)
2.	Muñoz, Miguel: 14 articles (09/2020 - 06/2004)
3.	Coveñas, Rafael: 12 articles (09/2020 - 07/2005)
4.	Arora, Sujata: 11 articles (01/2019 - 09/2015)
5.	Wang, Jing: 10 articles (10/2019 - 12/2017)
6.	Wang, Xiaodong: 10 articles (10/2019 - 12/2017)
7.	Zhang, Zhi-Yi: 10 articles (10/2019 - 12/2017)
8.	Kansra, Vikram: 9 articles (10/2019 - 12/2017)
9.	Jordan, Karin: 8 articles (01/2021 - 04/2016)
10.	Lu, Sharon: 8 articles (03/2019 - 12/2017)

Related Diseases

1.	Vomiting 01/01/2004 - "Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials." 12/01/2011 - "Neurokinin-1 receptor antagonists are effective in reducing the incidence of vomiting, but not nausea. " 01/01/2014 - "In clinical trials there is a singular success: neurokinin 1 receptor antagonists to treat nausea and vomiting. " 07/01/2018 - "While neurokinin-1 receptor antagonists (NK-1RAs) effectively prevent emesis, their ability to prevent nausea has not been established. " 11/01/1998 - "A neurokinin-1 receptor antagonist reduced hypersalivation and gastric contractility related to emesis in dogs."
2.	Nausea 12/01/2011 - "Neurokinin-1 receptor antagonists are effective in reducing the incidence of vomiting, but not nausea. " 01/01/2014 - "In clinical trials there is a singular success: neurokinin 1 receptor antagonists to treat nausea and vomiting. " 07/01/2018 - "While neurokinin-1 receptor antagonists (NK-1RAs) effectively prevent emesis, their ability to prevent nausea has not been established. " 05/01/2016 - "This meta-analysis was performed to evaluate the efficacy of neurokinin-1 receptor antagonists (NK1RAs) for the prevention of chemotherapy-induced nausea and vomiting (CINV) across different categories of chemotherapeutic emetogenicity. " 05/01/2016 - "Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis."
3.	Neoplasms (Cancer) 01/01/2018 - "Synthesis and Evaluation of a Novel 64Cu- and 67Ga-Labeled Neurokinin 1 Receptor Antagonist for in Vivo Targeting of NK1R-Positive Tumor Xenografts." 03/01/2006 - "After reviewing the role of both SP and its receptor NK1R in normal and neoplastic cells we propose the use of neurokinin-1 receptor antagonists as a novel and promising approach for treating patients with cancer." 01/01/2018 - "Neurokinin-1 receptor antagonist (NK1RA)-containing regimens are the standard regimens for CINV prophylaxis in patients with cancer receiving highly or moderately emetogenic chemotherapy (HEC or MEC). " 09/20/2020 - "The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?" 08/18/2020 - "Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors."
4.	Pruritus (Itching) 04/01/2021 - "Neurokinin 1 Receptor Antagonists for Pruritus." 05/01/2019 - "This study assessed safety and efficacy of the neurokinin 1 receptor antagonist serlopitant for treatment of pruritus in PN. " 06/01/2020 - "To examine the effects of serlopitant, an oral, once-daily neurokinin 1 receptor antagonist, for treatment of psoriatic pruritus in a phase 2, randomized clinical trial (NCT03343639). " 01/01/2017 - "Finally, we administered aprepitant, an oral neurokinin-1 receptor antagonist, for her refractory pruritus. " 01/01/2020 - "To evaluate the efficacy of orvepitant (10 or 30 mg given once daily, orally for 4 weeks), a neurokinin-1 receptor antagonist, compared with placebo in reducing the intensity of epidermal growth factor receptor inhibitor (EGFRI)-induced intense pruritus. "
5.	Pancreatitis 09/10/2012 - "Our aim was to assess the efficacy of a neurokinin-1 receptor antagonist (aprepitant) at preventing post-ERCP pancreatitis in high risk patients. " 09/01/2004 - "Endoscopic retrograde cholangiopancreatography-induced acute pancreatitis can be reduced experimentally by intraductal neurokinin-1 receptor antagonist and clinically by use of diclofenac and pancreatic duct stenting. " 02/01/2010 - "We compared the efficacy of the combination of the galanin antagonist galantide and the neurokinin-1 receptor antagonist L703,606 with that of either alone in the treatment of acute pancreatitis. " 05/01/2009 - "Moreover, treatment with the substance P receptor antagonist CP96345 [(2S,3S)-cis-2-(diphenylmethyl)-N-((2-methoxyphenyl)-methyl)-1-azabicyclo(2.2.2.)-octan-3-amine] attenuated acute pancreatitis-induced activation of SFKs, ERK, JNK, STAT3, NFkappaB, and AP-1. "

Related Drugs and Biologics

1.	Aprepitant (Emend)
2.	Antiemetics
3.	Cisplatin (Platino)
4.	Dexamethasone (Maxidex)
5.	Carboplatin (JM8)
6.	Palonosetron (Aloxi)
7.	Olanzapine (Zyprexa)
8.	Ondansetron (Zofran)
9.	maropitant
10.	Serotonin (5 Hydroxytryptamine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Injections
3.	Therapeutics
4.	Punctures
5.	Ligation